These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. How antibodies block HIV infection: paths to an AIDS vaccine. Putney S Trends Biochem Sci; 1992 May; 17(5):191-6. PubMed ID: 1350693 [TBL] [Abstract][Full Text] [Related]
3. HIV-1 recombinant gp160 vaccine given in accelerated dose schedules. Clin Exp Immun 1994;98:178-84. DePalma L Pediatr AIDS HIV Infect; 1995 Apr; 6(2):97-8. PubMed ID: 11361387 [No Abstract] [Full Text] [Related]
4. Presence of cross-reactive antibody between human immunodeficiency virus (HIV) and platelet glycoproteins in HIV-related immune thrombocytopenic purpura. Bettaieb A; Fromont P; Louache F; Oksenhendler E; Vainchenker W; Duédari N; Bierling P Blood; 1992 Jul; 80(1):162-9. PubMed ID: 1611083 [TBL] [Abstract][Full Text] [Related]
5. Cross-neutralizing antibodies to HIV-1 in mice after immunization with gp160 iscoms. Dissection of the immune response. Akerblom L; Nara P; Dunlop N; Morein B AIDS Res Hum Retroviruses; 1991 Jul; 7(7):621-7. PubMed ID: 1768464 [TBL] [Abstract][Full Text] [Related]
6. Current progress in HIV vaccines. Westblom TU; Belshe RB; Gorse GJ Mo Med; 1991 Nov; 88(11):762-5. PubMed ID: 1805131 [No Abstract] [Full Text] [Related]
7. Envelope-specific antibodies in the saliva of individuals vaccinated with recombinant HIV-1 gp160. Vasudevachari MB; Uffelman KW; Kovacs J; Yeh CK; Lane HC; Salzman NP J Acquir Immune Defic Syndr (1988); 1992; 5(8):817-21. PubMed ID: 1517967 [TBL] [Abstract][Full Text] [Related]
8. AIDS vaccine boosts immunity in HIV patients. RN; 1991 Oct; 54(10):103. PubMed ID: 1925340 [No Abstract] [Full Text] [Related]
9. Induction of HIV type 1 neutralizing and env-CD4 blocking antibodies by immunization with genetically engineered HIV type 1-like particles containing unprocessed gp160 glycoproteins. Rovinski B; Rodrigues L; Cao SX; Yao FL; McGuinness U; Sia C; Cates G; Zolla-Pazner S; Karwowska S; Matthews TJ AIDS Res Hum Retroviruses; 1995 Oct; 11(10):1187-95. PubMed ID: 8573374 [TBL] [Abstract][Full Text] [Related]
10. HIV. The modern era of HIV-1 vaccine development. Mascola JR Science; 2015 Jul; 349(6244):139-40. PubMed ID: 26160931 [No Abstract] [Full Text] [Related]
11. A 2-year follow-up of an anti-HIV immune reaction in HIV-1 gp160-immunized healthy seronegative humans: evidence for persistent cell-mediated immunity. Picard O; Achour A; Bernard J; Halbreich A; Bizzini B; Boyer V; Desgranges C; Bertho JM; Lachgar A; Polliotti B J Acquir Immune Defic Syndr (1988); 1992; 5(6):539-46. PubMed ID: 1588488 [TBL] [Abstract][Full Text] [Related]
12. Protection of chimpanzees from infection by HIV-1 after vaccination with recombinant glycoprotein gp120 but not gp160. Dis Markers; 1991; 9(1):51. PubMed ID: 1742945 [No Abstract] [Full Text] [Related]
13. Studies of antibody-dependent enhancement of human immunodeficiency virus (HIV) type 1 infection mediated by Fc receptors using sera from recipients of a recombinant gp160 experimental HIV-1 vaccine. Haubrich RH; Takeda A; Koff W; Smith G; Ennis FA J Infect Dis; 1992 Mar; 165(3):545-8. PubMed ID: 1538159 [TBL] [Abstract][Full Text] [Related]
14. Augmentation of human immunodeficiency virus type 1 neutralizing antibody by priming with gp160 recombinant vaccinia and boosting with rgp160 in vaccinia-naive adults. The NIAID AIDS Vaccine Clinical Trials Network. Graham BS; Matthews TJ; Belshe RB; Clements ML; Dolin R; Wright PF; Gorse GJ; Schwartz DH; Keefer MC; Bolognesi DP J Infect Dis; 1993 Mar; 167(3):533-7. PubMed ID: 8095059 [TBL] [Abstract][Full Text] [Related]
15. Production of long-lived neutralizing antibodies to HIV-1 IIIB in mice with a vaccinia recombinant virus-infected cell vaccine expressing gp160. Parry C; McLain L; Dimmock NJ AIDS Res Hum Retroviruses; 1994 Feb; 10(2):205-12. PubMed ID: 8198873 [TBL] [Abstract][Full Text] [Related]
16. Evaluation of gp160 vaccinees in the hu-PBL-SCID mouse model. Mosier DE; Gulizia RJ; MacIsaac P; Mathieson BJ; Smith G; Hu SL; Corey L; Greenberg P AIDS Res Hum Retroviruses; 1992 Aug; 8(8):1387. PubMed ID: 1466962 [No Abstract] [Full Text] [Related]
17. Neutralizing antibodies against HIV-1 BRU and SF2 isolates generated in mice immunized with recombinant vaccinia virus expressing HIV-1 (BRU) envelope glycoproteins and boosted with homologous gp160. Hu SL; Klaniecki J; Dykers T; Sridhar P; Travis BM AIDS Res Hum Retroviruses; 1991 Jul; 7(7):615-20. PubMed ID: 1768463 [TBL] [Abstract][Full Text] [Related]
18. Characterization of a vaccinia-derived recombinant HIV-1 gp160 candidate vaccine and its immunogenicity in chimpanzees. Barrett N; Eder G; Dorner F Biotechnol Ther; 1991; 2(1-2):91-106. PubMed ID: 1845126 [TBL] [Abstract][Full Text] [Related]
19. Antibody and cellular responses after HIV immunization. Wahren B J Acquir Immune Defic Syndr (1988); 1994 Sep; 7(9):989. PubMed ID: 8051623 [No Abstract] [Full Text] [Related]
20. Immunization with envelope subunit vaccine products elicits neutralizing antibodies against laboratory-adapted but not primary isolates of human immunodeficiency virus type 1. The National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group. Mascola JR; Snyder SW; Weislow OS; Belay SM; Belshe RB; Schwartz DH; Clements ML; Dolin R; Graham BS; Gorse GJ; Keefer MC; McElrath MJ; Walker MC; Wagner KF; McNeil JG; McCutchan FE; Burke DS J Infect Dis; 1996 Feb; 173(2):340-8. PubMed ID: 8568294 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]